Respiratory disease

American Lung Association Joins Forces with Laura Dern and CVS Health to Raise COVID-19 Research Funds

Tuesday, June 23, 2020 - 2:00pm

CHICAGO, June 23, 2020 /PRNewswire/ --Award-winning actress Laura Dern is partnering with the American Lung Association and CVS Health to tackle the respiratory disease that has affected us all: COVID-19.

Key Points: 
  • CHICAGO, June 23, 2020 /PRNewswire/ --Award-winning actress Laura Dern is partnering with the American Lung Association and CVS Health to tackle the respiratory disease that has affected us all: COVID-19.
  • Dern has partnered with the American Lung Association since 2015 through its LUNG FORCE initiative to defeat lung cancer, a cause near and dear to her heart.
  • As a long-time partner of the American Lung Association, CVS Health has signed on as a leading sponsor of their COVID-19 Action Initiative.
  • The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research.

Renovion Announces Completion of $8.1 Million Financing Round Enabling Clinical Programs in Chronic Inflammatory Lung Diseases

Thursday, June 18, 2020 - 1:00pm

Renovion, Inc., a biopharmaceutical company on a mission to transform the treatment of chronic inflammatory lung diseases, announced completion of a Series A financing round of $8.1 million to fund the development and clinical programs associated with their lead therapeutic candidate ARINA-1.

Key Points: 
  • Renovion, Inc., a biopharmaceutical company on a mission to transform the treatment of chronic inflammatory lung diseases, announced completion of a Series A financing round of $8.1 million to fund the development and clinical programs associated with their lead therapeutic candidate ARINA-1.
  • ARINA-1 is a nebulized therapy developed to improve mucus clearance and decrease inflammation in patients diagnosed with chronic lung disease.
  • This funding will be instrumental in progressing our clinical programs in patients suffering from chronic lung diseases, including patients with a lung transplant, cystic fibrosis (CF), and non-CF bronchiectasis.
  • The company is focused on developing ARINA-1 for orphan chronic inflammatory lung diseases.

miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd

Tuesday, June 16, 2020 - 9:01pm

Dr. Martinezs interests include chronic obstructive pulmonary disease (COPD), interstitial lung disease, lung transplantation, and lung volume reduction.

Key Points: 
  • Dr. Martinezs interests include chronic obstructive pulmonary disease (COPD), interstitial lung disease, lung transplantation, and lung volume reduction.
  • Ms. Barnes is a research advocate who is an ally for patients suffering from lung and fibrotic diseases.
  • miRagen undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law.
  • Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

Clearing The Air: Why Air Purifiers Are The "It" Home Device Of 2020

Tuesday, June 16, 2020 - 2:00pm

The American Lung Association reports that poor indoor air quality can contribute to the development of infections, lung cancer, and chronic lung diseases such as asthma3.

Key Points: 
  • The American Lung Association reports that poor indoor air quality can contribute to the development of infections, lung cancer, and chronic lung diseases such as asthma3.
  • One way the CDC recommend improving indoor air quality is to utilize air cleaners4.
  • Passive Cleaning air purification only works on the air that passes through the device's filter.
  • Sharp Air Purifiers use TrueHEPA filtration to capture 99.97% of the pollutants from the air that passes through the filter from 0.3 microns or larger.

Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19

Monday, June 15, 2020 - 2:00pm

SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (Adamis) announced today a license to commercialize Tempol, a novel patented investigational drug for the treatment of Coronavirus (COVID-19).

Key Points: 
  • SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (Adamis) announced today a license to commercialize Tempol, a novel patented investigational drug for the treatment of Coronavirus (COVID-19).
  • The license includes the worldwide use of Tempol for the treatment of all respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19.
  • In addition, the exclusive license includes the use of Tempol for reducing radiation dermatitis in patients undergoing treatment for cancer.
  • In severe cases, this can progress to pneumonia, acute respiratory distress syndrome (ARDS), acute cardiac injury and eventually death.

aTyr Pharma Announces Dosing of First Patient in Phase 2 Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

Monday, June 15, 2020 - 12:00pm

ATYR1923 is currently being evaluated in a Phase 1b/2a multi-center trial for patients with pulmonary sarcoidosis, a serious inflammatory lung disease.

Key Points: 
  • ATYR1923 is currently being evaluated in a Phase 1b/2a multi-center trial for patients with pulmonary sarcoidosis, a serious inflammatory lung disease.
  • The Phase 2 clinical trial is a randomized, double blind, placebo-controlled study of ATYR1923 in hospitalized COVID-19 positive patients with severe respiratory complications who do not require mechanical ventilation.
  • aTyr is currently enrolling a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in patients with pulmonary sarcoidosis, a form of interstitial lung disease.
  • In response to the COVID-19 pandemic, aTyr recently initiated a Phase 2 clinical trial with ATYR1923 in COVID-19 patients with severe respiratory complications.

Sanofi to present growth opportunities and development strategy for Dupixent® (dupilumab) in type 2 inflammatory diseases

Thursday, June 11, 2020 - 6:00am

While atopic dermatitis and asthma are the foundational diseases where Dupixent was first approved for use, great opportunity exists across multiple diseases where type 2 inflammation plays a role.

Key Points: 
  • While atopic dermatitis and asthma are the foundational diseases where Dupixent was first approved for use, great opportunity exists across multiple diseases where type 2 inflammation plays a role.
  • In the U.S., approximately 160,000 patients with EoE are currently treated, of which an estimated 50,000 have failed multiple treatments.
  • Chronic Obstructive Pulmonary Disease (COPD) with Evidence of Type 2 Inflammation Dupixent may benefit COPD patients with evidence of type 2 inflammation.
  • With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device

Monday, June 8, 2020 - 2:05pm

MINNEAPOLIS, June 8, 2020 /PRNewswire/ -- Nuvaira , a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that its Nuvaira Lung Denervation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • MINNEAPOLIS, June 8, 2020 /PRNewswire/ -- Nuvaira , a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that its Nuvaira Lung Denervation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA).
  • Nuvaira's lung denervation system is designed to reduce the risk of moderate-to-severe COPD exacerbations in patients on optimal medical care.
  • Nuvaira also announces appointment of Tim Herbert, President & CEO of Minneapolis-based Inspire Medical Systems to its Board of Directors.
  • Nuvaira and dNerva are registered trademarks of Nuvaira, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/nuvaira-announces-fda-breakthrou...

Vapotherm to Present at the William Blair 40th Annual Growth Stock Conference

Wednesday, June 3, 2020 - 12:00pm

Vapotherm is scheduled to present at 5:00 pm Eastern Time (4:00 pm Central Time).

Key Points: 
  • Vapotherm is scheduled to present at 5:00 pm Eastern Time (4:00 pm Central Time).
  • The company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders.
  • Over 2.2 million patients have been treated with Vapotherm Hi-VNI Technology.
  • Website Information Vapotherm routinely posts important information for investors on the Investor Relations section of its website, http://investors.vapotherm.com/ .

Global Airway Clearance System Market (2019 to 2026) - Opportunity Analysis and Industry Forecast - ResearchAndMarkets.com

Tuesday, June 2, 2020 - 3:21pm

The "Airway Clearance System Market by type, Application: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Airway Clearance System Market by type, Application: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.
  • Airway clearance techniques are used to slacken thick, sticky mucus so it can be cleared from lungs by coughing or huffing.
  • Rise in The prevalence of cystic fibrosis, asthma, chronic obstructive pulmonary disease (COPD) across the globe is the major factor driving the airway clearance market growth.
  • By end user, the hospitals segment dominated the market in 2018 and is anticipated to maintain its dominance during the forecast period.